Senior insider sale
President and CEO at ENLIVEN THERAPEUTICS, INC. — senior position signals high conviction
$4.79M
187.50K shares
What this filing means
KINTZ SAMUEL plans to sell 187.50K shares of ENLIVEN THERAPEUTICS, INC. valued at approximately $4.79M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 2/17/2026ACC: 0001974158-26-000019
DirectorOfficer· President and CEO
Since Feb 2023
187.50K
Shares to sell
$4.79M
Approx. market value
75K
Acquired (3 months)
1
Planned
5 completed
Securities Acquired — Last 3 Months1
Founder Shares
n/a
9/1/2019
75KTotal acquired75K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
9/1/2019 | Founder Shares n/a | 75K | — |
| Total | 75K | ||
Planned & Completed Dispositions6
Completed
—Completed
Units to sell
5K
Market value
$145.2K
2/6/2026
—Completed
Units to sell
20K
Market value
$535.1K
1/20/2026
—Completed
Units to sell
43.74K
Market value
$1.09M
1/9/2026
—Completed
Units to sell
38.76K
Market value
$930.3K
1/8/2026
—Completed
Units to sell
5K
Market value
$81.9K
12/17/2025
Planned — Approximate Date
NasdaqPlanned
Units to sell
75K
Market value
$2.00M
2/17/2026
Total
Units
187.50K
Value
$4.79M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
2/6/2026 | 5K | $145.2K | — | Completed |
1/20/2026 | 20K | $535.1K | — | Completed |
1/9/2026 | 43.74K | $1.09M | — | Completed |
1/8/2026 | 38.76K | $930.3K | — | Completed |
12/17/2025 | 5K | $81.9K | — | Completed |
| Planned — Approximate Date | ||||
2/17/2026 | 75K | $2.00M | Nasdaq | Planned |
| Total | 187.50K | $4.79M | ||